GlassScriptPhysician profile
Grace T Padron
NPI 1225393556
$4,692.16
in general payments reported to CMS, 2019-2025
19 companies · $345 in 2025
The $345 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $816 · 2022: $2,109 · 2023: $1,259 · 2024: $164 · 2025: $345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,768.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,767.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,125.69 | 2022-2025 | Dupixent |
| Glaxosmithkline, LLC. | $910.97 | 2021-2025 | Nucala, Trelegy Ellipta, Shingrix |
| Genzyme Corporation | $831.12 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $760.92 | 2021-2025 | Airsupra, Fasenra, Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $188.18 | 2021-2024 | Hyqvia |
| Amgen INC. | $182.52 | 2021-2022 | |
| Regeneron Pharmaceuticals, INC. | $128.12 | 2023 | Dupixent |
| Genentech USA, INC. | $113.14 | 2022-2023 | Xolair |
| Optinose US, INC. | $112.69 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $83.95 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $43.25 | 2023-2025 | |
| Octapharma USA, INC. | $41.37 | 2021-2022 | |
| Pfizer INC. | $38.40 | 2021-2023 | |
| Kaleo, INC. | $28.12 | 2021-2022 | |
| Abbvie INC. | $27.39 | 2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $24.04 | 2023 | Orladeyo |
| Csl Behring | $19.96 | 2021 | |
| Pharming Healthcare, INC. | $16.76 | 2022 | |
| Galderma Laboratories, L.P. | $15.57 | 2025 | Nemluvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Padron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.